Provectus Biopharmaceuticals (PVCT) Shares are Down -30.36%

Provectus Biopharmaceuticals (PVCT) : During the past 4 weeks, traders have been relatively bearish on Provectus Biopharmaceuticals (PVCT), hence the stock is down -38.73% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -30.4% relative to the S&P 500. The 4-week change in the price of the stock is -38.1% and the stock has fallen -30.36% in the past 1 week.

The stock has recorded a 20-day Moving Average of 32.47% and the 50-Day Moving Average is 41.06%. Provectus Biopharmaceuticals (NYSEMKT:PVCT): stock turned positive on Friday. Though the stock opened at $0.1974, the bulls momentum made the stock top out at $0.2297 level for the day. The stock recorded a low of $0.19 and closed the trading day at $0.195, in the green by 8.33%. The total traded volume for the day was 1,549,415. The stock had closed at $0.18 in the previous days trading.


The company Insiders own 10.4% of Provectus Biopharmaceuticals shares according to the proxy statements. Institutional Investors own 4.26% of Provectus Biopharmaceuticals shares.

Provectus Biopharmaceuticals, Inc. is a development-stage biopharmaceutical company. The Company is engaged in developing pharmaceuticals for oncology and dermatology indications. The Company is focused on developing its prescription drug candidates PV-10 and PH-10. It is developing PV-10 for treatment of several life threatening cancers, including metastatic melanoma, liver cancer, and breast cancer. It is developing PH-10 to provide minimally invasive treatment of chronic severe skin afflictions, such as psoriasis and atopic dermatitis, a type of eczema. All of its prescription drug candidates are in either the pre-clinical or clinical trial stage. In addition to clinical trials, patients enrolled in the expanded access or compassionate use program for PV-10 are also receiving PV-10 treatments for cutaneous and subcutaneous cancer indications.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.